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INTRODUCTION:  Postsurgical  chylothorax  is  a rare complication  of  cervical  dissection  for thyroid  cancer.
We  report  that octreotide,  a synthetic  analog  of  somatostatin,  is  effective  in treating  chylothorax  after
thyroid  carcinoma  surgery.
PRESENTATION  OF  CASE:  The  patient  was  a 48-year-old  woman  who  presented  to our  institution  com-
plaining  of  a left anterior  cervical  mass.  We  diagnosed  this  as  thyroid  papillary  carcinoma  and  performed
a  subtotal  excision  of  the  thyroid  gland  with  left  cervical  lymph  node  dissection.  The  patient  developed
dyspnea,  and  a chest  X-ray  revealed  bilateral  chylothorax  on  Day  4  post-surgery.  Octreotide  was  admin-
istered  since  bilateral  chylothorax  was  noted.  A  marked  decrease  in  chyle  effusion  was  noted  just 3  days
after starting  octreotide,  and  after  a total  of  9 days  of  treatment,  there  were  no  further  signs  of  chylous
effusion.
DISCUSSION:  Octreotide  is effective  against  postsurgical  chylothorax;  however,  if there  are  no  signs of
improvement,  we  believe  surgical  treatment  should  be  considered.
CONCLUSION:  Octreotide  should  be  administered  ﬁrst to treat postsurgical  chylothorax  before  surgical
treatment  is  considered.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Postsurgical chylous leakage is a rare complication of cervical
issection for thyroid cancer, but even rarer are cases where the
hyle effusion accumulates in the thoracic cavity and leads to chy-
othorax. When this condition persists, the patient can develop
lectrolyte disorders, malnutrition, and even become immunocom-
romised. Respiratory complications such as dyspnea can occur,
nd appropriate treatment should be instituted at an early stage.
hylothorax treatment can involve both conservative and surgical
ethods. However, the synthetic somatostatin analog, octreotide,
s reportedly effective against postsurgical chylothorax and has
ow become standard treatment. We  would like to report our expe-
ience with a case where octreotide administration was  effective
gainst bilateral chylothorax that occurred after cervical dissection
or thyroid carcinoma.
. Presentation of caseThe patient was a 48-year-old woman. Past medical history and
amily medical history were unremarkable. She also had no history
f smoking. A hard, immobile 3 cm × 3 cm-sized nodule could be
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palpated in the left anterior cervical area. The CT showed a 3-cm-
sized poorly contrasted region in the left lobe of the thyroid gland
with lymphadenopathy of the left supraclavicular lymph nodes
(Fig. 1A–C). Needle aspiration cytology diagnosed the mass as a pap-
illary carcinoma. From the above, the patient was diagnosed with
papillary thyroid carcinoma where the primary lesion was found in
the left lobe of the thyroid, and a subtotal thyroidectomy with cen-
tral and lateral neck dissection was  performed by thyroid cancer
specialists. Surgical ﬁndings included a 3-cm-diameter mass in the
left lobe of the thyroid gland with inﬁltration into the sternothyroid
muscle. Some left deep cervical lymph nodes were swollen with
adhesion to the subclavian vein but were not inﬁltrating into the
internal carotid artery, internal jugular vein, or recurrent laryngeal
nerve. We  performed a subtotal thyroidectomy according to the
Japanese guideline [1]. We  did not obviously encounter or injure
the thoracic duct during the procedure. Histopathologic ﬁndings
showed a tumor with a 2.8 cm diameter. It was  a thyroid papillary
carcinoma that inﬁltrated into the sternothyroid muscle and thy-
mus. We found 4 involved lymph nodes in 22 dissected neck nodes.
Metastases to lymph nodes level IV, level Vb, and level VI were
noted. On Day 1 post-surgery, drainage from the tube inserted in
front of the trachea was  80 mL.  There was  no drainage effusion and
the patient was allowed to start oral alimentation on Day 2. How-
ever, she developed dyspnea on Day 4 post-surgery. A chest X-ray
revealed bilateral pleural effusions, and when the thoracic cavity
was drained bilaterally, a total of 1400 mL  of chylous drainage was
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
CASE  REPORT  –  OPEN  ACCESS
108 N. Hayashibara et al. / International Journal of Surgery Case Reports 21 (2016) 107–110
Fig 1. A: Neck CT: a poorly contrasted 3 cm-diameter mass was  noted in the left lobe of the thyroid. B: Neck CT: left deep cervical lymphadenopathy was noted. C: Neck CT:
left  supraclavicular lymphadenopathy was noted.
Fig. 2. Chest X-ray: an image from Day 4 post-surgery revealed bilateral chylotho-
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uctioned off (Fig. 2). The patient was diagnosed with postsurgical
hylothorax and placed on a fat-restricted diet and administra-
ion of 50 g/day of octreotide. The day after the drug was  started,
rainage volume decreased to 110 mL/day on Day 3 of administra-
ion, and no effusion was collected at all by Day 9 (Fig. 3). EvenFig. 3. Chest X-ray: an image from Day 15 post-surgery showed no signs of chy-
lothorax.
after restarting oral alimentation, chylothorax did not recur, and
the patient was  discharged on Day 20 post-surgery (Fig. 4).Chylous leakage is a relatively uncommon complication and is
said to occur in about 1–2% of cases after cervical dissection [2].
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aig. 4. Changes in daily chyle drainage over time. After administration of octreotide,
hylous drainage decreased markedly.
ince only some of the patients suffering chylous leakage will go
n to develop chylothorax, the incidence of chylothorax is believed
o be even lower than 1–2%.
Patients who present with respiratory symptoms due to a
uildup of chylous effusion must ﬁrst have their thoracic cavity
rained. Once the thoracic ﬂuid is drained, the following will occur:
he lungs will be able to re-inﬂate; the respiratory symptoms will
e alleviated; the intrathoracic cavity will shrink; and the chylous
eakage can be expected to improve as well [3].
There are 2 ways to treat chylothorax: conservative therapy or
urgery. Chylous effusion volume is an important criterion when
eciding whether to attempt conservative treatment. At drainage
olumes of 500 mL/day or less, 50–83% of chylothorax cases have
eportedly been cured with conservative treatment [4,5]. On the
ther hand, in cases where the chyle drainage exceeds 1 L per day,
t is highly unlikely that the thoracic duct wound will close with
ust conservative therapy, and surgery would be indicated in such
ases [6,7]. If there is no improvement after continuing conservative
herapy for 1–2 weeks or more, surgery should be performed in
rder to avoid serious malnutrition and sepsis [8,9].
Conservative treatment of chylothorax includes the following:
I) implementing fat-restricted diets or fasting with central venous
utrition, limiting the intake of long-chain triglycerides and imple-
enting dietary treatment to inhibit the production of chyle [3];
II) instituting pharmacotherapy and administering octreotide, a
ynthetic somatostatin analog, or etilefrine which stimulates the
ympathetic nervous system to inhibit chyle production and limit
ymph ﬂow in the thoracic duct by constricting thoracic duct
mooth muscle [10]; or (III) performing pleurodesis using tetra-
ycline, minomycin, or OK-432 [11,12].
Surgical treatment consists of: (I) wound retraction or thoracic
uct ligation by video-assisted thoracic surgery (VATS) [13,14];
II) percutaneous thoracic duct cannulation and insertion of an
ndwelling metal coil for thoracic duct embolization [15]; and (III)
n cases where all of these treatments are ineffective, establishing
 thoraco-peritoneal shunt [16].
Octreotide is a synthetic somatostatin analog comprising 8mino acids. It inhibits secretion of various digestive hormones
uch as glucagon and insulin, and digestive juices such as gastric
cid, pancreatic ﬂuid, and bile, and thereby decreases blood ﬂow toPEN  ACCESS
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the internal organs which decreases the lymph ﬂow [17]. This drug
also constricts smooth muscle via the somatostatin receptors in
the lymph duct endothelium and smooth muscles [18]. Octreotide
is believed to decrease the thoracic duct ﬂow rate through these
mechanisms of action.
Recent papers reported that octreotide is effective against
postsurgical chylothorax [19,20]. These reports suggest that chy-
lothorax improvement can be seen as early as 2–3 days after
starting octreotide. If there are no signs of improvement after 3
days of treatment, it is highly likely that the drug will not be effec-
tive. However, there is no consensus on how to administer this drug
for chylothorax. Some reports have suggested a dose of 600 g/day
while others report that chylothorax improved on a 150 g/day
dose regimen [21]; thus, an optimized dosage and administration
method should be established in the future. In our case, the patient
presented with dyspnea on Day 4 after surgery, and 1400 mL  of
chylothorax effusion was  drained through a thoracic tube. Since
there were no signs of chylous drainage from the cervical drain,
all of the chyle that leaked from the thoracic duct was believed to
have come from chyle contained in the thoracic cavity. A total of
1400 mL  of chyle collected in the thoracic cavity during the 4 days
from immediately after surgery up to the thoracic cavity drainage.
Therefore, the mean daily chyle drainage was 350 mL/day, a level at
which conservative treatment is indicated. The patient was  there-
fore placed on a fat-restricted diet and octreotide was  administered
subcutaneously at a dose of 50 g/day. The chylothorax improved
after 3 days of drug administration, and conservative treatment
was continued. By Day 7 after starting octreotide, the drainage
had decreased markedly to only 20 mL/day. We  were thus able
to achieve a cure after only 9 days of octreotide administration.
In our case, the dose was 50 g/day of octreotide. This means we
were successful in alleviating the chylothorax with a very low dose
compared to the standard dose of octreotide, which ranges from
150 g/day to 600 g/day.
4. Conclusion
To treat chylothorax that develops after thyroid papillary
carcinoma surgery, the clinician should ﬁrst attempt to con-
tinue conservative treatment, including pharmacotherapy with
octreotide. In cases where there is no sign of improvement, it would
be reasonable to consider another operation.
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